Discovery helps explain how B cells adapt to their targets

May 7, 2014 by Zach Veilleux
Discovery helps explain how B cells adapt to their targets
As the immune system fights an infection, it selects B cells that target the pathogen. A new study helps explain how the highest affinity B cells are selected. Above, red B cells in a lymph node form germinal centers where selection takes place. T cells, critical in this process, are green.

(Medical Xpress)—Over the weeks following an invasion by a disease-causing microbe, the human immune system fine tunes its defenses, producing proteins called antibodies that are ever more precisely targeted at the invader. New research in Michel Nussenzweig's Laboratory of Molecular Immunology helps explain how the immune system accomplishes this, suggesting new ways by which the body could be trained to fight disease.

"We have understood this process, called affinity maturation, in broad strokes for decades; however, the mechanistic details have remained more elusive," says Alex Gitlin, a graduate student in the lab and the first author of a study that delves into these mechanisms. "Our research helps explain how the immune system selects B cells that produce with a high affinity for a pathogen."

B cells are specialized that make antibodies that bind to foreign molecules, called antigens, on the surface of microbes. Prior to an infection, the body has a diverse repertoire of B cells, each capable of producing a unique antibody. During an infection or vaccination, B cells whose antibodies bind the antigen form microanatomical structures called germinal centers in the lymph nodes and spleen.

Within germinal centers, the B cells evolve. The gene responsible for producing their antibodies mutates rapidly, one million-fold faster than the normal rate of mutation in the human body, and the cells proliferate. Then, the B cells capable of producing antibodies with the highest affinity to the antigen are selected.

"These cycles of mutation, proliferation and selection happen over and over again. Over time, a few lines of high affinity B cells come to dominate the germinal centers," Gitlin says. Their current findings shed light on how the higher affinity B cells out-compete lower affinity cells.

Ultimately, the high affinity B cells survive and can protect the body should the same microbe be re-encountered later on. Vaccines take advantage of this process, using weakened versions of pathogens to imitate an infection. As a result, a better understanding of how the immune system adapts its defenses will help with vaccine development, including one against HIV.

In research described this week in Nature, Gitlin and colleagues at Rockefeller looked at what happens to B cells during their time in the two zones of the germinal center. In the "dark" zone, B cells mutate and proliferate before traveling to the "light" zone, where those with antibodies that bind best to the microbial antigens are selected. The B cells then continue to divide, returning to the dark zone.

While in the light zone, the B cells pick up bits of antigen from the invader and display them on their surface. The key finding is that specialized T cells in the light zone recognize higher affinity B cells based on the amount of antigen those B cells display. In response, the T cells provide a stronger signal to those higher affinity B cells, instructing them to stay longer in the dark zone and undergo a greater number of cell divisions.

The research team used a combination of techniques that allowed them to measure the history of cell division in the germinal center, as well as where each cell division is initiated, and how long the B spent in the dark zone.

The repeated process of hypermutation and selection creates a feed-forward loop, says Gitlin. "When a B cell is selected as being higher affinity, it is instructed by the T cell to divide a greater number of times, and through more cell divisions, they accumulate more mutations."

The importance of antibody hypermutation is best exemplified by HIV. The HIV virus mutates rapidly, but through a large amount of hypermutation and selection, the is capable of producing broad and potent antibodies against it. Previous work in the lab has identified antibodies from the blood of patients to broadly neutralize variants of HIV.

Explore further: Disease-causing IgE antibodies are regulated to avoid allergic responses

More information: "Clonal selection in the germinal centre by regulated proliferation and hypermutation." Alexander D. Gitlin, et al. Nature (2014) DOI: 10.1038/nature13300. Received 17 January 2014 Accepted 01 April 2014 Published online 04 May 2014

Related Stories

Disease-causing IgE antibodies are regulated to avoid allergic responses

April 23, 2014
The immunoglobulin E (IgE) antibody released by the immune system is a pivotal defense against gut parasites and toxins. However, the same antibody when misdirected can also cause allergic responses to food or substances ...

Specialized regulatory T cell stifles antibody production centers

July 25, 2011
A regulatory T cell that expresses three specific genes shuts down the mass production of antibodies launched by the immune system to attack invaders, a team led by scientists at The University of Texas MD Anderson Cancer ...

How infection can trigger autoimmune disease

November 9, 2012
Australian scientists have confirmed a 'weak link' in the immune system – identifying the exact conditions under which an infection can trigger an autoantibody response, a process not clearly understood until now.

Macrophages target tumor cells following monoclonal antibody therapy

January 16, 2014
Monoclonal antibodies directed against tumor antigens have proven effective for treating some forms of cancer. Despite the increasing use of monoclonal antibody therapy, it is not clear how these antibodies drive tumor removal.

Lymph node roundabout: Researchers probe origin of optimized antibodies against infections

June 28, 2012
An organism's ability to make new antibodies and use them to optimize its own immune defenses is of central importance in the fight against pathogens. In the case of severe infections, the overall relative speed with which ...

Recommended for you

Want to win at sports? Take a cue from these mighty mice

July 20, 2017
As student athletes hit training fields this summer to gain the competitive edge, a new study shows how the experiences of a tiny mouse can put them on the path to winning.

'Smart' robot technology could give stroke rehab a boost

July 19, 2017
Scientists say they have developed a "smart" robotic harness that might make it easier for people to learn to walk again after a stroke or spinal cord injury.

Engineered liver tissue expands after transplant

July 19, 2017
Many diseases, including cirrhosis and hepatitis, can lead to liver failure. More than 17,000 Americans suffering from these diseases are now waiting for liver transplants, but significantly fewer livers are available.

Lunatic Fringe gene plays key role in the renewable brain

July 19, 2017
The discovery that the brain can generate new cells - about 700 new neurons each day - has triggered investigations to uncover how this process is regulated. Researchers at Baylor College of Medicine and Jan and Dan Duncan ...

New animal models for hepatitis C could pave the way for a vaccine

July 19, 2017
They say that an ounce of prevention is worth a pound of cure. In the case of hepatitis C—a disease that affects nearly 71 million people worldwide, causing cirrhosis and liver cancer if left untreated—it might be worth ...

Omega-3 fatty acids fight inflammation via cannabinoids

July 18, 2017
Chemical compounds called cannabinoids are found in marijuana and also are produced naturally in the body from omega-3 fatty acids. A well-known cannabinoid in marijuana, tetrahydrocannabinol, is responsible for some of its ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.